MedPath

Effect of Captopril on GLS in Duchenne Myodystrophy

Early Phase 1
Recruiting
Conditions
Effect of Drug
Interventions
Registration Number
NCT06485661
Lead Sponsor
Ain Shams University
Brief Summary

To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)

Detailed Description

ACEI slowing down the onset and the progression of dystrophinopathic cardiomyopathy.

To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
20
Inclusion Criteria
  • Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS < -18% with minimum age of 6 years old.
Exclusion Criteria
  • Any patient who refuses to sign an informed consent.
  • Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
  • Reduced ejection fraction below 50%.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Duchenne patients subjected to captoprilCaptopril Tablets-
Primary Outcome Measures
NameTimeMethod
The impaired global longitudinal strain will change in echo in the number of participants with duchenne myodystrophy6 months

Impaired Global longitudinal strain will be changed in echo after 6 months of treatment with Captopril in patients with duchenne myodystrophy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ain Shams university

🇪🇬

Cairo, Egypt

Ain Shams university
🇪🇬Cairo, Egypt
Fatma Ebeid, MD
Contact
00201095569596
dr.fatma_ebeid@yahoo.com
Sandra M Mina
Contact
01060781869
sandramourad922@yahoo.com
Mona M Rayan, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.